Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Genmab - ADR
GMAB

Buy GMAB Stock

GMAB
See GMAB stock price and Buy/Sell Genmab - ADR with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
GMAB

Genmab - ADR (GMAB)

About Genmab - ADR (GMAB)

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra fo...Read more
Market Cap
$19.25B
1 Year High
$49.07
Volume
399.89k
1 Year Low
$27.42
Price to Earnings Ratio
40.17
Open
$30
Dividend Rate
High
$30.38
Dividend Yield
Low
$29.64

Community

People who own or watch GMAB stock

GMAB Stock News

GMAB stock rating

What analysts recommend for GMAB stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
2

GMAB price target

What analysts think GMAB will be worth
Low $27.42
High $49.07
Current $30.29
Target $40.61

Events

List of events that could affect GMAB stock.
11May

Earnings data Q1 2022

10Aug

Earnings data Q2 2022

GMAB earnings

The value each share was expected to gain vs. the value that each share actually gained
0.22
0.14
0.07
0
Q3 2021
Q4 2021
Q1 2022
Q2 2022

Expected EPS
Q2 2022
$0.18
Actual EPS
Q2 2022

Buy GMAB Stock

GMAB
See GMAB stock price and Buy/Sell Genmab - ADR with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch GMAB stock
  • SAH123456 avatar
  • WillRobinson55 avatar
  • will4u27 avatar
  • pbarros avatar
  • faisalahmed157 avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.